The 2024 American Society of Clinical Oncology (ASCO) conference showcased significant advancements in cancer research, with AstraZeneca's drugs, Tagrisso and Enhertu, demonstrating notable efficacy. Tagrisso (osimertinib) showed an 84% reduction in disease progression or death in patients with unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC) compared to placebo, with a median time to progression or death of 39 months versus 5.6 months with placebo, according to the LAURA Phase III trial. Enhertu (fam-trastuzumab deruxtecan-nxki) exhibited a median progression-free survival of 13.2 months in HR-positive, HER2-low, and HER2-ultralow metastatic breast cancer, surpassing chemotherapy. These findings suggest Enhertu could become a new standard of care for patients with HER2 low and ultralow expressing tumors. The event underscored the evolving landscape of cancer treatment, with a focus on targeted therapies and immunotherapies. AstraZeneca's immunotherapy Imfinzi also showed a survival extension of 23 months in early-stage lung cancer patients.
Astra's Enhertu breast cancer trial shows 'unprecedented' results https://t.co/kuFgDjqApy https://t.co/kuFgDjqApy
For the few that care, Astrazeneca really been dominating the oncology game. Tagrisso reduces chance of lung cancer progression by 84% and Enhertu cut chances cut the risk of disease progression or death by 37% versus chemo in ultra low breast cancer https://t.co/ChFvOYFCPr
📢 $AZN's Tagrisso (osimertinib) for Stage III cancer ! #ASCO #CancerResearch #Cancer #LungCancer https://t.co/whJkfthiLR
WATCH: Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC @ramalingammd @WinshipAtEmory @EmoryUniversity @ASCO #ASCO24 https://t.co/9SxQTkqK3Z
While sharing #LCSM research at #ASCO24, @DavidRSpigel presented #ADRIATIC Phase III trial outcome of IMFINZI (durvalumab). Amazing news for the patients. #ASCO #lungcancer #sclc #lcsm https://t.co/54DG0rOHJm
ASCO 2024: @BeiGeneGlobal CEO @johnvoyler discusses the breadth of the company's pipeline at #ASCO24. $BGNE Full video: https://t.co/SGbsaLYlnD https://t.co/4iNCmdiW32
ASCO 2024: @AulosBioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24. Full video: https://t.co/E7GmnwPKyX https://t.co/pLYD75h5g9
Exciting TIP poster by @antgiorda at #ASCO24: Phase 3 Trial to test PF-07220060, a next-gen CDK4 inhibitor, combined w/fulvestrant to combat resistance in HR+/HER2− advanced #BreastCancer. A previous 1st-in-human phase 1/2a study found 29% objective response rate. @DanaFarber https://t.co/dNanNlIs08
Another AstraZeneca story at #ASCO24 (3rd breakthru, random tweet order by me): "immunotherapy Imfinzi helped people in early stages of a type of lung cancer live 23 months longer than those who received just chemoradiotherapy, according to clinical trial data released Sunday." https://t.co/5VTefLrYi2
Another big AstraZeneca story from #ASCO24 (3rd breakthru, not in order): "immunotherapy Imfinzi helped people in early stages of a type of lung cancer live 23 months longer than those who received just chemoradiotherapy, according to clinical trial data released Sunday." $AZN https://t.co/5VTefLrYi2
“With a median progression-free survival of > a year, the results from DESTINY-Breast06 show that Enhertu could become a new standard of care for patients with HER2 low and HER2 ultralow expressing tumors following endocrine therapy in the metastatic setting," #ASCO24 said… https://t.co/KFfFuy9Num
Whoa. In patients with stage 3 lung cancer positive for EGFR mutations, a new drug 'Tagrisso' greatly reduced the chance of cancer progression or metastasis. The median time to progression or death was 5.6 months with placebo vs 39 months with the drug. https://t.co/kh1hBHTghq
"The findings suggest Enhertu should be used before chemotherapy in a common type of advanced breast cancer. They may also usher in a new classification for breast tumors — those with 'ultralow,' but still detectable, levels of HER2 protein." #ASCO24 $AZN $DSNKY https://t.co/9gURnujPfz
Home run! LAURA: Osimertinib after chemoRT in EGFR-mutated unresectable stage III NSCLC. @ASCO https://t.co/ZeXJESEX33
Breakthrough for stage 3 lung cancer patients w/EGFR mutations: "More than 80% of trial participants were of Asian descent; EGFR mutations are more common in this group. This type of cancer often occurs in nonsmokers, & > 2/3 of participants said they never smoked." #ASCO24 $AZN https://t.co/1a77PZx8N2
LAURA passes the "truck test" to a rousing ovation at #ASCO24 plenary session, with osimertinib given to patients with locally advanced unresectable stage III EGFRmut NSCLC with no progression following definitive chemoRT #lcsm https://t.co/K8Iwlc9Rbv https://t.co/SXIbtFohJf
WATCH: @RamalingamMD on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC @ASCO #ASCO24 #lcsm #oncology https://t.co/9SxQTkqK3Z
$AZN Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC (LAURA) #ASCO24 | New England Journal of Medicine https://t.co/DTsi8lcE3Q https://t.co/PC61vUNGXi
🔟🎙️ “We heard more on the important CHECKMATE 8HW clinical trial from Dr. Heinz Lenz today. Single🆚combination immunotherapy🆚 chemo. While we await what NIVO arm does🆚IPI/NIVO, checkpoint inhibition is SOC✅ for 1st line MSI-High colorectal cancers.” @pashtoonkasi #ASCO24 https://t.co/rIDaKJwOzJ
Astra's Enhertu breast cancer trial shows 'unprecedented' results https://t.co/y9m9j7UzQD https://t.co/y9m9j7UzQD
9️⃣🎙️ “Another trial for patients with MSS colorectal cancers of note utilized this new 🎯 - ADENOSINE⛔️. This was in combination with FOLFOX➕BEV➕PD1⛔️. Comparator: REGOrafenib. Unknowns are contribution of components since FOLFOX rechallenge works too.” @pashtoonkasi #ASCO24 https://t.co/JT0i6Ani5p
🎙️8️⃣ “Can’t talk about immunotherapy for MSI-High cancers only. Highlighting Dr. @mgfakih poster presentation looking into BOT 🤖 (novel CTLA4⛔️)➕BAL (PD1⛔️) in MSS #colorectalcancer. 💡👇🏾It appears peritoneal & other unfavorable sites responded✅ too 💭.” @pashtoonkasi #ASCO24 https://t.co/IwQBQEw0g0
AstraZeneca’s Enhertu breast cancer trial shows ‘unprecedented’ results https://t.co/NiTPgXUosj
7️⃣ 🎙️ “Staying on the neoadjuvant theme, want to bring to your attention the first randomized trial looking at: PD1⛔️➕/➖CTLA4⛔️ This time again in MSI-High colorectal cancers. 👇🏾Looked like another #ChalabiPlot💦. Don’t need adjuvant chemo➡️💡#ctDNA” @pashtoonkasi #ASCO24 https://t.co/kfAc6FKLK9
5️⃣🎙️“Perfect timing⏱️to highlight another neoadjuvant study as we hear the discussants elaborate on this paradigm shift. 👀 at👇🏾plot 💦. Higher response rate from PD1⛔️alone due to⬆️more time to brew 🫖. Here➡️~12 weeks. Neoprism trial @KaiKeenShiu👏🏾.” @pashtoonkasi #ASCO24 https://t.co/SgzR3HJdWC
4️⃣🎙️”It was sobering to note that going after radical procedures and resections in patients with “extensive” multi-organ metastatic #colorectalcancer doesn’t improve survival. 🔌Important to enroll in ongoing trials. @ALLIANCE_org ERASUR. ≠ definitions.” @pashtoonkasi #ASCO24 https://t.co/NAvjSgPxg0
AstraZeneca's Tagrisso Shows 84% Reduction in Disease Progression in Trials https://t.co/iD6bU8IiEb
3️⃣🎙️”Next I wanted to highlight the results of the Collision💥randomized trial answering the question of ablation🆚surgery for liver metastases from #colorectalcancer where feasible. 👇🏾Ablation not a backup to surgery based on this trial” @pashtoonkasi #ASCO24 https://t.co/GQ3182sI4Z
2️⃣🎙️“NADINA trial being presented by @ProfCUBlankNKI is hard to ignore even as a GI oncologist. The neoadjuvant paradigm shift➡️happening across solid tumors. Many reasons why in particular doing #immunotherapy neoadjuvant is superior compared to adjuvant.” @pashtoonkasi #ASCO24 https://t.co/egegrPODek
🎙️”It was provocative to hear in on results of a randomized trial of TRANSPLANT for patients with #colorectalcancer and unresectable liver metastases! Increasingly of note there are centers in that have started doing transplant. Rigorous selection is 🔑.” @pashtoonkasi #ASCO24 https://t.co/TUAeSsWSqN
ASCO 2024: The CEO of @arcusbio talks TIGIT, adenosine, and HIF-2α at #ASCO24. $RCUS Full video: https://t.co/xM3D2w7Cop https://t.co/lEgoCyKitr
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial https://t.co/F5NvWFteMz https://t.co/hEPYlwChap
Session alert this afternoon at @ASCO, by @LiaPalomba. #ASCO24 https://t.co/lHkmhtihGE
Presented at #ASCO24: Among patients with EGFR-mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo. Full LAURA trial results: https://t.co/NvZXToy84j https://t.co/Ma4JpFTRM0
Dr. Chrisann Kyi presented research from a phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab at #ASCO24. ⬇️ https://t.co/Bk9dWcFnHH
Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer @curijoey @ASCO #ASCO24 #bcsm https://t.co/OT4yiKtol2
ASCO 2024: @DaiichiSankyoUS leadership comments on DESTINY-Breast06 at #ASCO24. Full video: https://t.co/IgizQ4v91d https://t.co/S1JEUCSAR6
Don’t miss @AdamJSchoenfeld’s poster session, now through 12pm (CT)! #ASCO24 https://t.co/JjNQZhvWxA
Astra's Enhertu delays breast cancer in patients with low HER2 levels https://t.co/wxhtPmfSYV https://t.co/iACNMAgIKH
Today at #ASCO24: Endpoints of the DESTINY-Breast03 trial of #TrastuzumabDeruxtecan or trastuzumab emtansine in patients with HER2+ #BreastCancer are reported, including updated efficacy & safety data with a median follow-up of 41 months. @JavierCortesMD https://t.co/ZHZonQPo0B
Join gynecologic oncologist & early drug development specialist Dr. Chrisann Kyi as she discusses her phase 1 #cancerresearch during an oral session titled "Developmental Therapeutics—Immunotherapy" at @ASCO. More: https://t.co/gCwNOcS7LD #ASCO24 📅: 6/2 at 12:36pm (CT) https://t.co/oK2isXbHLm
With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment, @adamfeurstein writes https://t.co/dx2hTMrxV5
Start your day off right with #ASCO24 posters! @SherryShenMD will present results of a study on sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib & everolimus in patients w/ hormone receptor-positive metastatic #breastcancer @ASCO @MSKCancerCenter 💠 9 a.m. CT | Hall A https://t.co/xf6XPZKKFg
Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer @ASCO @DanaFarber @DFCI_BreastOnc #bcsm #ASCO24 https://t.co/IYZRDImQIQ
Poster sessions continue today in Hall A at #ASCO24. Please stop by from 9am-12pm CDT to view the research posters from @BraunMDPhD, @DanielPetrylak, @danoneilmd1, @maryam_lustberg, @Joseph_W_Kim, @NicoleOdzer and more! https://t.co/5dspKCLqpC @SmilowCancer @YaleMed @YNHH https://t.co/DIbjTp90hC
At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer. https://t.co/07XCKv0nZT
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer https://t.co/ddgCmJDI5o @ByJonGardner $AZN $RHHBY #ASCO24
$AZN $DSNKY Enhertu nears its “ultralow” dream, but #ASCO24 discussant is careful not to describe Destiny-Breast06 as practice changing for all. 3/436 patients died of ILD. Via @ApexOnco -> https://t.co/qmp4ZeLCzd
Laura's crossover conundrum - should Tagrisso be used before stage III NSCLC patients progress? Via @ApexOnco from #ASCO24 -> https://t.co/QiyKnHhsry $AZN
New: With new Enhertu data, an ADC could overtake chemo in breast cancer https://t.co/LXuv1whwBt $AZN $DSNKY #ASCO24
Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC @RamalingamMD @ASCO #ASCO24 #lcsm #oncology https://t.co/jv4pf1ztc8
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy https://t.co/NAJoLTBO3M https://t.co/mlAQusPpz9
A Sunday morning #ASCO24 read: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment https://t.co/YCYDtcOLhc $DSNKY $AZN
Massive PFS benefit (HR=0.16) for Tagrisso in Laura trial of stage III EGFRm NSCLC. But note 81% rate of placebo patient crossover. Study effectively becomes OS comparison of maintenance Tagrisso vs Tagrisso on progression. Via S Ramalingam $AZN #ASCO24 https://t.co/jlMVcUJeft
👀 ADCs in Breast Cancer: Amazing ~80% ORRs with ~90% PFS at 1yr! #ASCO2024 #Daiichi https://t.co/moyk6e85jr
Another poster session from MSK researcher @GormallyMDPHD. #ASCO24. ⬇️ https://t.co/nD1QNORsfR
Saturday snapshots at #ASCO24: Ana Garrido-Castro, MD, MPH presents on the SACI IO HR + trial; Antonio Giordano, MD, PhD, (@antgiorda) presents the first data of the Nectin4 ADC enfortumab vedotin in metastatic breast cancer; and Lakshmi Nayak, MD, speaks with @Blood_Cancers https://t.co/1Xdd5VHsKV
Great representation from MSK at #ASCO24. https://t.co/xj9o52AP3Q
Research presented by MSK researchers ⬇️⬇️ at #ASCO24. https://t.co/WfLSDRdv6U
ASCO 2024: @nimbustx's CEO @JebKeiper on the company's HPK1 data at #ASCO24. Full video: https://t.co/oZvMI3i0gm https://t.co/EFvqalLIqM
ASCO 2024: @Summitplc's @JackWestMD on the company's PD-1xVEGF bi-specific vs Keytruda news. $SMMT Full video: https://t.co/JBydaQucb8 https://t.co/pAdSVREsbQ
Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression @KalinskyKevin @WinshipAtEmory @ASCO #ASCO24 #bcsm https://t.co/Dx73RxNIC8
WATCH: Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC @cbcbc1971 @yonsei_u @ASCO #lcsm #ASCO24 https://t.co/Kzh36RnyyK
ASCO 2024: @Immunocore's CEO and Head of R&D discuss the company's PRAME data at #ASCO24. $IMCR Full video: https://t.co/uhBiJqzgY3 https://t.co/CDQfjUWkcp
A special thank you to Dr Ana C. Garrido-Castro, @DanaFarber, who stopped by to discuss the phase 2 SACI-IO HR+ trial examining sacituzumab govitecan +/- pembrolizumab in metastatic HR+/HER2– breast cancer. For more, check out: https://t.co/McEtwvjaJu @ASCO #ASCO24 #bcsm https://t.co/BYtXPBfSWA
Adagrasib Improves Survival, Responses in KRASG12C-mutated Advanced NSCLC @TonyMok9 @ASCO #lcsm #Oncology #ASCO24 https://t.co/SQsfcziKUn
Antibody-drug conjugate + checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer - @DanaFarber study presented at #ASCO24 by Ana Garrido-Castro, MD CC: @stolaney1 @DFCI_BreastOnc https://t.co/2taYfjZWaI
Join thoracic oncologist & early drug development specialist Helena Yu as she discusses research on a phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant #lungcancer and active central nervous system disease at @ASCO. https://t.co/AH8B1GPHrz #ASCO24 https://t.co/66L4kAz0RC
ASCO 2024: The CEO of @CullinanTx discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease. Full video: https://t.co/cuFl24jOFg https://t.co/0zj23UKc60
Join breast oncologist Dr. Shanu Modi as she discusses research on the ongoing antibody–drug conjugates revolution in #breastcancer during an oral session at @ASCO. Learn more: https://t.co/w0qMFZ92We 📅: 6/1 at 4:36pm (CT) #ASCO24 https://t.co/6yVDuvzhw1
60% vs 8% 5-year progression-free survival (PFS). A breakthrough for a type of advanced lung cancer. https://t.co/8Lws1Y5fhR @JCO_ASCO @ASCO @bensolomon1 https://t.co/OZmvX3Wwam
Join @CentralParkWMD as he shares research from a phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors at @ASCO. Learn more: https://t.co/e9YCtDIfaI #ASCO24 📅: 6/1 at 3:24pm (CT) https://t.co/r6JD72ycEf
Join @CentralParkWMD at @ASCO where he'll discuss a Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors. Learn more: https://t.co/e9YCtDHHla #ASCO24 📅: 6/1 at 3:24pm (CT) https://t.co/sthibxhGWF
Check out #sarcoma posters at #ASCO24! Mrinal Gounder will share preliminary results from the FLAGSHP-1 phase 1 study of ERAS-601 as a monotherapy or in combination w/ cetuximab in patients previously treated for advanced chordoma. @ASCO @MSKCancerCenter 💠 1:30 p.m. CT | Hall A https://t.co/fKVjUKBBGd
Starting this afternoon at 1:15pm CDT/2:15 EST, Dr. Patricia LoRusso @AACRPres, Dr. Jennifer Kapo, @BraunMDPhD, @Annechiangmd, and Dr. Sarah Goldberg will be presenting in education sessions at #ASCO24. https://t.co/5dspKCKSA4 @SmilowCancer @YaleMed @YNHH https://t.co/lu3L0gVdEm
Join @CentralParkWMD for an oral abstract at @ASCO about the first-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) w/advanced solid tumors. https://t.co/e9YCtDIfaI #ASCO24 📅: 6/1 at 3:24pm (CT) https://t.co/cmKfIWbF1l
Join thoracic oncologist & early drug development specialist Dr. Bob Li as he discusses research on targeting KRAS in non-small cell #lungcancer during a clinical science symposium at @ASCO. Learn more: https://t.co/qA9fPJCMCx #ASCO24 📅: 6/1 at 1:15pm (CT) https://t.co/MnJCFHodUS